BackgroundHeart failure (HF) is the end stage of most heart disease. Mesenchymal stem cells (MSCs), with their specific biological effects, have been applied in several clinical trials to evaluate the efficacy in HF therapy. We performed this meta-analysis to review the clinical evidence of their therapeutic effect on HF.MethodsThree databases were searched. The outcomes of interest were death, readmission, the 6-min walk test (6MWT), New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF). The relative risk (RR) and weighted mean difference (WMD) were calculated to evaluate the effects of MSCs on HF compared to placebo.ResultsA total of nine studies were included, involving 612 patients who underwent MSCs or placebo treatment. The overall rate of death showed a trend of reduction of 36% (RR [CI]=0.64 [0.35, 1.16], p=0.143) in the MSC treatment group. The incidence of readmission was reduced by 34% (RR [CI]=0.66 [0.51, 0.85], p=0.001). The patients in the MSC treatment group realised an average of 40.44m (WMD [95% CI]=40.44m [19.07, 61.82], p<0.0001) improvement in 6MWT. The NYHA class was reduced obviously in the MSC group (WMD [95% CI]=-0.42 [-0.64, -0.20], p<0.0001). The changes of LVEF from baseline were significantly more than 5.25% (WMD [95% CI]=5.25 [3.58, 6.92], p<0.0001) in the MSCs group, unlike in the placebo group.ConclusionsOur results suggested that MSC treatment is an effective therapy for HF by improving the prognosis and exercise capacity. SCs derived from allosomes have superior therapeutic effects, and intracoronary injection is the optimum MSC delivery approach. Short-term cryopreservation is feasible in MSCs storage or transport.
[1]Fudan Univ, Zhongshan Hosp, Shanghai Inst Cardiovasc Dis, Dept Cardiol, 180 Fenglin Rd, Shanghai 200032, Peoples R China;
[2]Nantong Univ, Affiliated Hosp, Dept Geriatr Med, Nantong, Jiangsu, Peoples R China
(8.0+极速模式)